AbbVie Updates Q3, 2026 EPS Guidance to Include IPR&D Expense
MT newswire2026/10/05 21:0005:00 PM EDT, 10/05/2026 (MT Newswires) -- AbbVie (ABBV) said Monday it expects Q3 adjusted diluted EPS of $3.73 to $3.77, including acquired in-process research and development and milestones expense. The company previously expected Q3 adjusted diluted EPS of $3.84 to $3.88, excluding the expense. AbbVie expects Q3 results to include $216 million of the expense. For full-year 2026, AbbVie expects adjusted diluted EPS of $13.76 to $13.96, including $1.25 billion of acquired IPR&D and milestones expense.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
